A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Clinical Pharmacology Clinical Trial

Official title:

A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02113020
• Other study ID #: TAK-233/CPH-003
• Secondary ID: U1111-1152-9381
• Status: Completed
• Phase: Phase 1
• First received: February 21, 2014
• Last updated: October 20, 2014
• Start date: February 2014
• Est. completion date: September 2014

Study information

• Verified date: October 2014
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical trial is to examine the clinical pharmacology properties of TAK-233 in healthy female subjects

Description:

The primary objective of this study is to examine the pharmacodynamics and the safety of TAK-233 administered as a single dose in healthy women.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Subjects who understand the contents of this clinical trial and who the investigator or sub-investigator consider able to comply with the procedures of the clinical trial

2. Subjects who can sign the informed consent form and can date the form without assistance before starting the procedures of the clinical trial

3. Healthy Japanese women

4. Subjects aged = 20 and = 40 years at the time of consent

5. Subjects with body weight = 45 kg and BMI =18.5 and = 25.0 kg/m2 at the time of screening

6. Women of child bearing potential who agree to take specified contraceptive measures regularly from the time of consent until 4 weeks after the end of the last assessment in the fourth treatment period

Exclusion Criteria:

1. Subjects who received TAK-233 within 16 weeks before the start of initial administration

2. Subjects who have previously received TAK-233 during treatment or during participation in another clinical trial

3. Employees of the medical institution conducting this clinical trial and their family/dependents (e.g., husband or wife, parents, children, and siblings), or subjects who may be coerced to agree to participate in the clinical trial

4. Subjects with poorly controlled and clinically significant neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal (including chronic costiveness), urological (including dysuria), autoimmune, endocrine, or psychiatric diseases or other abnormalities which may affect the subject's participation in the clinical trial or results of the clinical trial

5. Subjects with hypersensitivity to TAK-233 related substances, or excipients of these products

6. Subjects whose urine tested positive for drug abuse at screening

7. Subjects with a history of drug abuse (defined as the use of illegal drugs) or alcohol dependence within 52 weeks before the screening assessments, or subjects who are not willing to stop alcohol intake or drug use during their participation in the clinical trial

8. Subjects who need to take prohibited concomitant medications, vitamins, or foods listed in listed in what?

9. Pregnant or lactating women, women expecting to be pregnant before giving consent, during this clinical trial, or within 4 weeks after the completion of this clinical trial, or women who are planning to donate their ova during this period

10. Subjects with currently active cardiovascular diseases, central nervous system diseases, hepatic diseases, hematopoietic diseases, renal failure, metabolic disorders, endocrine disorders, serious allergies, asthma, hypoxemia, hypertension, convulsion, allergic exanthema, or urological disorders (subjects with peptic ulcer, convulsive disorders, or arrhythmia also fall this category)

11. Subjects that have any of the following diseases/surgical interventions that may affect drug absorption: digestive system disorders (malabsorption, esophageal reflux, peptic ulcer, erosive oesophagitis, frequent heartburn (at least once a week), or surgical interventions (e.g., cholecystectomy), or subjects who have had prior history of any of these diseases/surgical interventions within the last 24 weeks

12. Subjects with a history of cancer (excluding subjects whose basal cell carcinoma has been in remission for at least 5 years

13. Subjects that have tested positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, or syphilis serological reaction at screening

14. Subjects who took nicotine-containing products (e.g., cigarette, pipe tobacco, cigar, chewing tobacco, nicotine patch, and nicotine gum) within 28 days before hospitalization

15. Subjects for whom blood collection from peripheral veins is difficult

16. Subjects who donated at least 200 mL of whole blood within 4 weeks before the start of the initial administration, or subjects who donated at least 400 mL of whole blood within 16 weeks before the start of the initial administration

17. Subjects who donated at least 400 mL (in total) of whole blood within 52 weeks before the start of the initial administration

18. Subjects who donated blood components within 2 weeks before the start of the initial administration

19. Subjects with clinically significant abnormalities on the electrocardiogram recorded at screening or hospitalization (Day -1 of the first treatment period)

20. Subjects who had a QTcF interval of > 470 msec or a PR interval of < 120 msec or > 220 msec on the electrocardiogram recorded at screening or hospitalization

21. Subjects with a systolic blood pressure of < 100 mmHg or > 140 mmHg and a diastolic blood pressure of < 60 mmHg or > 90 mmHg at screening or hospitalization

22. Subjects with a heart rate of < 50 bpm or > 90 bpm at screening or hospitalization

22. Subjects unlikely to comply with the protocol, or subjects the investigator or sub-investigator considers ineligible for participation in the clinical trial due to other reasons

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Clinical Pharmacology

Intervention

Drug:
• TAK-233
Oral administration of TAK-233
• Placebo
Oral admininstration of Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in motor threshold for urethral sphincter contraction.		0.5 hours post-dose	No
Primary	Change from baseline in motor threshold for urethral sphincter contraction.		3 hours post-dose	No
Primary	Change from baseline in motor threshold for urethral sphincter contraction.		6 hours post-dose	No
Secondary	Number of participants with adverse events	Treatment emergent adverse events, vital signs, weight, safety ECG, and clinical laboratory tests (hematology, serum chemistry, and urinalysis).	Up to 28 days	No